Abstract | AIM: To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results. METHODS: MEDLINE, EMBASE and Cochrane library databases were systematically searched through the end of May 2012. Meta-analysis of RCTs and cohort studies was performed to estimate the effects of the VK2 analog on tumor recurrence rate and overall survival (OS). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: Six RCTs and one cohort study involving a total of 930 patients were included. VK2 analog therapy did not reduce the 1-year recurrence rate, with a pooled RR of 0.67 (95% CI 0.39-1.13, p = 0.13). However, VK2 analog therapy was associated with a significant reduction in the 2- and 3-year tumor recurrence rates, with respective pooled RRs of 0.65 (95% CI 0.51-0.83, p<0.001) and 0.70 (95% CI = 0.58-0.85, p<0.001). The therapy was also associated with a significant improvement in 1-, 2-, and 3-year OS, with respective pooled RRs of 1.03 (95% CI 1.01-1.05, p = 0.02), 1.11 (95% CI 1.03-1.19, p = 0.005) and 1.14 (95% CI 1.02-1.28, p = 0.02). None of the studies reported adverse effects attributable to VK2 analog therapy. CONCLUSION: The VK2 analog may reduce recurrence rate after 1 year and improve OS in HCC patients as early as 1 year. However, these findings should be considered preliminary since the majority of patients came from an RCT with survival data out to only 1 year. More extensive studies with larger sample sizes and longer follow-up are needed.
|
Authors | Jian-Hong Zhong, Xin-Shao Mo, Bang-De Xiang, Wei-Ping Yuan, Jin-Fang Jiang, Gui-Sheng Xie, Le-Qun Li |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 3
Pg. e58082
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 23505456
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
|
Chemical References |
|
Topics |
- Carcinoma, Hepatocellular
(drug therapy, mortality, surgery)
- Chemoprevention
- Humans
- Liver Neoplasms
(drug therapy, mortality, surgery)
- Postoperative Care
- Publication Bias
- Recurrence
- Risk
- Treatment Outcome
- Vitamin K 2
(adverse effects, analogs & derivatives, therapeutic use)
|